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Summary
Intravenous lidocaine is used widely for its effect on postoperative pain and recovery but it can be, and has
been, fatal when used inappropriately and incorrectly. The risk-benefit ratio of i.v. lidocaine varies with type of
surgery and with patient factors such as comorbidity (including pre-existing chronic pain). This consensus
statement aims to address three questions. First, does i.v. lidocaine effectively reduce postoperative pain and
facilitate recovery? Second, is i.v. lidocaine safe? Third, does the fact that i.v. lidocaine is not licensed for this
indication affect its use? We suggest that i.v. lidocaine should be regarded as a ‘high-risk’medicine. Individual
anaesthetists may feel that, in selected patients, i.v. lidocaine may be beneficial as part of a multimodal peri-
operative pain management strategy. This approach should be approved by hospital medication governance
systems, and the individual clinical decision should be made with properly informed consent from the patient
concerned. If i.v. lidocaine is used, we recommend an initial dose of nomore than 1.5 mg.kg-1, calculated using
the patient’s ideal body weight and given as an infusion over 10 min. Thereafter, an infusion of no more than
1.5 mg.kg-1.h-1 for no longer than 24 h is recommended, subject to review and re-assessment. Intravenous
lidocaine should not be used at the same time as, or within the period of action of, other local anaesthetic
interventions. This includes not starting i.v. lidocaine within 4 h after any nerve block, and not performing any
nerve block until 4 h after discontinuing an i.v. lidocaine infusion.
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Recommendations
1 The use of intravenous (i.v.) lidocaine for acute pain
should be ratified and approved by the local hospital
andmedication governance committee, or equivalent.
2 Whenever possible, consent should be obtained from
patients if i.v. lidocaine is to be used, and a full appraisal of
thepossiblebenefits and risks ineachcaseundertaken.
3 Ideal body weight should be used for dose calculation.
Intravenous lidocaine should not be used in patients
weighing < 40 kg. For any patient, no more than
120 mg.h-1 should be infused.
4 Intravenous lidocaine should not be used at the same
time as, or within the period of action of, other local
anaesthetic interventions, particularly local anaesthetic
nerve blocks.
5 A loadingdoseof nomore than 1.5 mg.kg-1, given as an
infusion over 10 min, is recommended. Thereafter, an
infusion of no more than 1.5 mg.kg-1.h-1, for no longer
than 24 h, is recommended, subject to review and re-
assessment. This should be delivered from a suitable
infusion device through a separate, dedicated cannula.
There shouldbea separate lidocainemonitoring chart.
6 Outside the operating theatre/recovery room, patients
receiving i.v. lidocaine should ideally be managed in a
monitored bedspace in a high dependency unit (level
2 care). Particular vigilance is needed in patients with
existing comorbidity.
7 Clinicians should remember the possibility of toxicity
even though there may be other explanations for a
given clinical presentation. Lipid emulsion 20% should
be readily available wherever i.v. lidocaine is used, and
staff should knowwhere it is kept.
What other consensus statements are
available on this topic?
Although i.v. lidocaine is used widely in the management of
postoperative pain and recovery inmany regions of theworld,
no consensus statements on its use havebeenpublished.
Whywas this statement developed?
This statement was developed after an incident in an English
hospital where a patient died after being given i.v. lidocaine
postoperatively.
Howdoes this statement differ from
existing guidelines?
This is the first consensus statement. It aims to provide
practical recommendations on the safe use of i.v. lidocaine
for postoperative pain and recovery.
Introduction
Lidocaine (originally Xylocaine, and previously lignocaine)
was developed in the first half of the twentieth century and
approved for use in humans by the US Food and Drug
Administration in 1948 [1,2]. By 1958, intravenous (i.v)
lidocaine infusions were being used to provide
postoperative analgesia in clinical practice [3]. The
postoperative analgesic and antihyperalgesic effects of i.v.
lidocainewere confirmed in later studies [4,5].
Currently, i.v. lidocaine is used as a peri-operative
analgesic across a wide number of areas, including the
operating theatre, recovery room, intensive care unit (ICU)
and surgical ward [6]. In a recent survey in Scotland, 12 out
of the 16 responding hospitals were either already using i.v.
lidocaine infusions for acute pain, or were planning to use
them in the near future [7]. Lidocaine has anti-nociceptive,
anti-hyperalgesic and anti-inflammatory actions and it is
presumably these actions, rather than a direct local
anaesthetic effect, which explain the apparent prolonged
effect hours after an infusion has been completed [6,8–10].
Given the short- [11] and long-term [12] undesirable
effects of opioids, multimodal analgesic strategies are a key
component of postoperative pain management. However,
concerns have always existed about the narrow therapeutic
window and toxicity of lidocaine, both when given i.v. or as
part of a regional anaesthetic technique [13–15]. Lidocaine
has a multimodal mechanism of action. In therapeutic
concentrations during i.v. infusion, it blocks muscarinic (M1,
M3) and N-methyl-D-aspartate (NMDA) receptors. At higher
and near-toxic concentrations, many receptor types are
affected including: Nav1.8/1.7; purinoceptor 7 (P2X7); toll-
like receptor 4 (TLR4); 5-hydroxytryptamine-3 (5HT-3);
nicotinic cholinergic receptors; voltage-gated calcium
channels (VGCC); transient receptor potential ankyrin 1
(TRPA1); and acid-sensing ion channel (ASIC) [8]. It is
unsurprising, therefore, that the therapeutic index for i.v.
lidocaine is low, with central nervous system toxicity starting
at plasma levels only slightly higher than therapeutic levels.
The correlation of plasma levels with signs and symptoms of
toxicity is not linear [16], as systemic toxicity reflects the
unpredictable interaction between patient factors and the
pharmacokinetic and pharmacodynamics properties of the
drug [15]. This situation is compounded by the fact that data
on the systemic toxicity of i.v. lidocaine are seldom collected
in clinical trials [17].
Methodology of consensus statement
Recently, the death of a patient who had received an i.v.
infusion of lidocaine was reported to the Safe Anaesthesia
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Liaison group (SALG) of the Royal College of Anaesthetists.
This has been reported subsequently in the media [18]. It is
clear that the use of i.v. lidocaine is widespread [7]. While
informal experience gathered will tend to make the use of
i.v. lidocaine safer [19], there is nevertheless a need for a
complementary formal safety guideline. A multidisciplinary
group of experts and representatives of relevant
professional organisations was assembled to work on the
guideline. The aim of the working party was to analyse the
index safety incident, review and interpret the available
published literature on effectiveness and safety, and
provide recommendations for safe use of i.v. lidocaine in
peri-operative practice. The guideline was not intended to
apply to the use of i.v. lidocaine in the management of
chronic pain, either in outpatient or inpatient settings.
In assessing the research and other intelligence, we
sought to address three main questions. First, is i.v.
lidocaine effective in the treatment of postoperative pain?
Second, is it safe? Third, how does the fact that lidocaine is
not licensed affect how its use can be recommended?
Is intravenous lidocaine effective in the
treatment of postoperative pain?
Many randomised controlled trials have been conducted in
the last 15 years investigating the effect of i.v. lidocaine on
pain and postoperative recovery, with a number of
systematic reviews and meta-analyses having subsequently
been performed [17, 20–26]. The largest andmost recent of
these included patients undergoing any type of surgery
(4525 patients in 68 trials) [17]. These large numbers,
however, disguise the fact that for many outcomes the
volume of available data is much smaller, and hence less
robust. Most reviews focus on lidocaine’s analgesic effects,
whether measured as pain intensity or as analgesic
consumption, but some also examine other aspects of
postoperative recovery, including opioid-related adverse
effects such as postoperative ileus, incidence of nausea and
vomiting, and duration of stay in hospital.
However, just as individual trials vary greatly in
lidocaine dose, infusion rate, duration of infusion, outcomes
chosen and management of patients in the ‘control’ group,
there is heterogeneity among the meta-analyses with
respect to a number of important features. These include:
the range of surgical specialties and operations
incorporated; the primary outcome measure; the
assessment of methodological quality (risk of bias) of
included trials; the degree to which they take account, or
make use of, this quality assessment in their conduct of the
review; the detail of the scrutiny of the included studies in
general; the interpretation and presentation of the review
findings; and the extent to which their reflective discussion
deals withmethodological, rather than clinical issues.
To illustrate this point, we present a detailed analysis of
the available data for one outcome, postoperative pain
scores at 24 h in patients who have undergone abdominal
surgery, in the online Supporting Information
(Appendix S1). Themain points are summarised below.
The first four systematic reviews [20–23], published
between 2008 and 2012, drew on the same pool of primary
trials of lidocaine in abdominal surgery [27–42].
A further systematic review and meta-analysis by
Ventham et al. (including an author of this safety guideline,
IF) was published in 2015 [25] and included six further
studies [43–48]. The authors found a similar mean
difference (95%CI) in postoperative pain scores to previous
reviews (-0.42 (-0.79 to -0.04)), but were the first team to
point out the limited clinical significance of their findings,
stating in the discussion of their work that “in almost all
measured outcomes, the difference in pain score was less
than the 1.3 point reduction deemed clinically significant”
[49].
The varying degrees of methodological scepticism and
expertise in the authors’ work is illustrated by the various
approaches to the assessment of methodological quality of
primary studies, which included the Jadad score [50] (also
known as the ‘Oxford score’), a modification of the Jadad
score [51] or the risk of bias tool used in Cochrane
systematic reviews [52–54]. Sun et al. [23] used a further
modification of the Oxford scale [55,56], Chang et al. [24]
did not cite a method, and Ventham et al. [25] used yet
another modification of the Jadad score [57]. Numerical
scoring systems for study quality assessment have fallen out
of favour, as evidenced by the review by Vigneault et al. [22]
where the Jadad scale generally provided amore optimistic
view of study quality than the Cochrane tool. Twelve out of
the 29 studies (46%) were judged at low risk of bias by the
Cochrane tool compared with 23 (79%), which achieved a
Jadad score of ≥ 3, the usual cut-off point for ‘high’ quality.
This is echoed by other studies comparing numerical scores
with the Cochrane tool [58]; the Cochrane group actively
discourage the use of numerical scoring systems, as they
have a strong emphasis on reporting rather than conduct,
and may not cover one of the most important potential
biases in randomised trials, namely allocation concealment.
In addition, not all review authors used the information on
study quality to restrict their analysis to less biased studies
or perform sensitivity analyses excluding lower-quality
studies.
The trend of greater understanding and scepticism
continues in the Cochrane systematic reviews conducted by
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Weibel et al. (first published in 2015 [26] and updated in
2018 [17]). Pain scores were the primary outcome, drawing
on previous methodological work suggesting that
postoperative analgesic consumption is a less reliable
method of measuring analgesic efficacy as the distribution
of consumption is often highly skewed [59,60] and there are
opportunities for error in conversion when quantities such
as ‘morphine equivalents’ are calculated. In the first review
the authors used both the Cochrane risk of bias tool to
assess methodological quality [61] and the GRADE
(Grading of Recommendations, Assessment, Development
and Evaluations) system to appraise the quality of evidence
on the basis of the extent to which one can be confident that
the estimate of effect reflects the item assessed [62].
The 2018 update [17] incorporated 23 new trials, taking
the total number of studies to 68. Out of these, 22 examined
open abdominal surgery and 20 laparoscopic surgery,
including (in addition to a new study in the 2015 version
[63]), a further seven trials [64–70] measuring pain at 24 h.
The authors also noted that a number of studies reported
small variances, and added the novel methodological
feature of 95% prediction intervals. These provide an index
of dispersion (based on the SD) that suggests how widely
the mean effects vary across populations; reporting a
prediction interval in addition to the summary estimate and
CI illustrate what range of true mean effects might be
expected in future settings, and is also helpful in the clinical
interpretation of heterogeneity. Weibel et al [17] suggested
that i.v. lidocaine reduced pain scores 0–4 h after surgery,
with a standardisedmean difference (SMD (95%CI)) of -0.50
(-.72 to -0.28) (29 studies, 1656 patients). This equated to a
reduction of between 0.37 cm and 2.48 cm on a visual
analogue scale (VAS). There was no evidence of a clinically
relevant effect on pain scores at 24 h or 48 h, with the
authors noting that the standardised mean difference of
-0.14 in average pain score would be equivalent to a mean
pain reduction in the order of 0.48 cm to 0.10 cm on a 10-
cm VAS (depending on the variance of the study). Further,
the 95%prediction intervals “crossed the line of identity, and
the range of true mean effects mostly remained in areas of
clinical non-relevance” [17]. However, the patients in the
control groups in many of the primary studies had free
access to other analgesics; this can lead to smaller
differences in pain scores between groups, and makes
benefit harder to demonstrate.
A primary outcome of pain score is perhaps, therefore,
the wrong outcome to focus upon. Overall postoperative
opioid consumption was reduced, with the mean difference
(95%CI) being -4.52 (-6.25 to -2.79) mg morphine
equivalents (40 studies, 2201 patients) although the range
of true mean effects included areas of clinical non-
relevance. The incidence of ileus did appear to be reduced,
however, with a risk ratio (RR) (95%CI) 0.37 (0.15–0.87) (four
studies, 273 participants). For the time to first bowel
movement, the mean difference (95%CI) was reduced by
7.92 (12.71–3.13) h (12 studies, 684 participants). The risk of
postoperative nausea was also reduced, with a risk ratio
(95%CI) of 0.78 (0.67–0.91) (35 studies, 1903 participants).
The quality of evidence was very low for most of these
outcomes, however, and ultimately the authors concluded it
was uncertain if “i.v. lidocaine, when compared to placebo
or no treatment, has a beneficial impact on pain scores in the
early postoperative phase, and on gastrointestinal recovery,
postoperative nausea, and opioid consumption”.
The systematic reviews drew on a limited pool of small
primary studies, and even taken together, the data are
rather sparse [71,72]. They are similar, though, where they
reflect the primary trials that they include, as patients who
might be expected to be at greater risk of postoperative
pain (those already taking analgesics or experiencing long-
term pain) were not included. Where the meta-analyses
differ is more in the authors’ understanding of, and
scepticism towards, the conduct of the primary trials [64].
These findings demonstrate that the risk-benefit decision to
use i.v. lidocaine needs to reflect the type of surgery and the
patient’s condition.
Is lidocaine safe?
There are a number of ways of evaluating the safety of i.v.
lidocaine. These include: attempts to establish relationships
between plasma lidocaine concentrations and toxicity; the
infusion regimens used; occurrence of symptoms and signs
of toxicity; the documentation of adverse events within
clinical studies; and analyses of specific serious problems.
Plasma lidocaine concentrations and toxicity
Early studies investigating lidocaine toxicity infused i.v.
lidocaine at a rate of 30 mg.kg-1.h-1; this is about 10–20
times higher than modern day regimens, which are typically
12 mg.kg-1.h-1 [73]. Adverse events appeared rapidly.
Further evidence that speed of infusion was important came
from Bromage et al. [74] while Gianelly et al. suggested in a
small study of 29 patients, that blood levels associated with
serious toxicity were about 9–10 lg.ml-1 and to avoid toxic
effects (central nervous system depression, convulsions and
hypotension), the dose should be kept < 3 mg.kg-1.h-1 [75].
Sawyer et al. studied continuous infusions of lidocaine
in patients with cardiac arrhythmias [76]. In 26 patients an
appropriate bolus dose (0.5–4 mg.kg-1) was followed by an
infusion varying between 1 mg.min-1 and 4 mg.min-1, as
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determined by the patients’ physicians, rather than a fixed
dosage regimen. This resulted in a range of lidocaine
plasma concentrations from 1.65 lg.ml-1 to 11.33 lg.ml-1
[76]. Lidocaine clearance values were highly variable. Some
of these early studies used lidocaine doses that were not
based on patient weight, included small numbers of
patients, and had a poorer understanding of the factors
affecting clinical toxicity; however, these studies do provide
some pointers to the relationship between plasma
concentration and toxicity.
Apart from the dose and speed of i.v. lidocaine as
determinants of lidocaine toxicity, duration of infusion is
also important. Rowland et al. studied disposition kinetics of
lidocaine in normal subjects [77]. The half-life of lidocaine
was shown to be approximately 100 min following either a
bolus or an infusion lasting < 12 h. For infusion
durations> 12 h, lidocaine showed non-linear or time-
dependent pharmacokinetics. LeLorier et al. examined this
further by studying the pharmacokinetics of lidocaine after
prolonged i.v. infusions (> 24 h) in patients with
uncomplicated myocardial infarction [78]. Twelve patients
with no evidence of renal, hepatic or heart failure were given
a bolus of 1 mg.kg-1 of lidocaine followed by an infusion of
1.2 mg.kg-1.h-1. Using pharmacokinetic modelling, the
mean half-life of the elimination phase was found to be
3.22 h after 24 h, in contrast to the 100 min when infused
for less than 12 h. This suggested that lidocaine
pharmacokinetics were linear and predictable only up to
12 h, leading to recommendations that after 24 h, the rate
of lidocaine infusion be reduced to approximately 50%even
in patients without cardiac and hepatic failure. This
inconsistency between observations and recommendation
is in the original paper.
Within the peri-operative clinical setting, McCarthy
et al. reported plasma lidocaine concentrations from seven
of their included studies [27,30,31,33,79–81] in their
systematic review [20]. Concentrations were measured after
bolus injection and at different time intervals during and
after infusion. Toxic concentrations (defined as > 5 µg.ml-1)
were not reached in any study following lidocaine infusion,
with the exception of one asymptomatic patient presenting
with a peak value of 5.8 lg.ml-1 measured 5 min after
lidocaine bolus [30]. Mean plasma lidocaine concentrations
ranged from 0.58 µg.ml-1 to 5 µg.ml-1. The highest plasma
lidocaine concentration at 24 h was 4.6 lg.ml-1 after
infusion of 1.33 mg.kg-1.h-1 for 24 h [31]. Plasma
concentrations ranged between 2 lg.ml-1 and 5 lg.ml-1
when infused for 48 h at a rate of 30 lg.kg-1.min-1 [77]. In
the study by Cassuto et al.[27] where lidocaine was given as
a 100 mg bolus followed by infusion of 2 mg.min-1 for 24 h
postoperatively, whole blood lidocaine concentrations
averaged 1.52 lg.ml-1 8 h after the start of infusion and 1.75
µg.ml-1 after 20 h. Table 1 lists studies which: measured
plasma lidocaine concentrations after a bolus dose of
1.5 mg.kg-1 (our recommended dose); where a fixed
infusion rate was used; and where the results were reported
as mean (SD). Figure 1 displays the spread of plasma
concentrations obtained at three infusion rates.
Patient factors predisposing to toxicity
The relationship between dose and plasma lidocaine
concentrations is not completely clear-cut [16, 74, 82]. Such
differences may be explained by understanding the
pharmacokinetics of lidocaine in different patient
populations [83]. In heart failure, volume of distribution and
plasma clearance are significantly reduced. Lidocaine
clearance correlates with cardiac index, as this influences
hepatic blood flow and therefore lidocaine clearance.
Lidocaine is metabolised to mono-ethylglycinexylidide
and glycinexylidide by hepatic enzymes. Mono-
ethylglycinexylidide has similar pro-convulsant and anti-
arrhythmic properties to lidocaine itself but is rapidly
converted to glycinexylidide by the liver, which is in turn
excreted by the kidney [87]]. Thus patients with hepatic or
renal impairment are more susceptible to developing
lidocaine toxicity [88]. Plasma clearance is reduced in liver
failure, whereas in renal failure patients have a similar
clearance to normal subjects; however, authors have
speculated that the metabolites might accumulate during
prolonged infusion. Several other factors may influence
lidocaine toxicity including acid-base status (acidaemia
increases the dissociation of lidocaine from plasma
proteins) and hypoxaemia [89]. Hypoalbuminaemia and
other conditions where plasma proteins are depleted
increase the amount of free drug in the plasma and hence
make toxicity more likely. Drugs which reduce lidocaine
metabolism (e.g. beta-blockers) and clearance (e.g.
amiodarone)may enhance lidocaine toxicity, especially with
prolonged infusions. Inducers and inhibitors of the hepatic
enzyme cytochrome P450 can also have an effect. However,
studies in the last 15 years have not specifically reported
any adverse effects related to drug interactions as far as we
are aware. Low body weight can result in a reduction in
skeletal muscle mass (which normally acts as a storage
reservoir for local anaesthetic) and may be associated with
an increased frequency of adverse reactions [90]. However,
patients with high body mass index (BMI) may also have
inadvertently higher plasma concentrations [16, 91]; this
may be because actual, rather than ideal, body weight is
used for dose calculation. This notion is supported by Dale
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et al., who showed that patients’ actual plasma
concentrations were 20% higher than predicted when
actual body weight was used [91]. Some studies have
weight exclusions, for example, < 45 kg and > 100 kg [44],
which may have reduced the risk of adverse events. Two
further safety measures are to have an upper infusion rate
limit (e.g. 120 mg.h-1) irrespective of body weight
calculations and to use ideal body weight rather than actual
bodyweight in lidocaine infusion calculations.
Adverse events in clinical studies and analysis of serious
adverse events
Fifty of the 68 studies included in the most recent Cochrane
review gave information on adverse events [17]. In 23 of
these studies, no significant events were reported, while in
the remaining 27, only minor adverse effects such as
drowsiness, light-headedness, peri-oral numbness, tinnitus
and bradycardia were described. A recently reported large
series showed minor adverse events in 37 (6.8%) of the 544
patients in whom i.v. lidocaine had been used [92]. These
included: six patients complaining of somnolence and
metallic taste; five patients with dizziness; four patients with
agitation; and three patients each reporting nausea, peri-
oral numbness, tinnitus and tremor. As already discussed,
there are many factors which influence plasma lidocaine
concentration and clinical evidence of toxicity, but
catastrophic events are usually due to human error in
dosing, infusion programming or infusion of thewrong drug
[9]. These factors were in evidence in the report of an
incident in a UK hospital where a patient died during an
infusion of i.v. lidocaine. Here, a number of contributing
factors were identified [81, 86]. The patient had undergone
several abdominal operations in the preceding 18 months,
and appeared to have had pain that was difficult to control
postoperatively. Both pre-existing systemic factors [93, 94]
and communication difficulties [95, 96] appear to have
played their part in this unfortunate death.
In summary, although there appears to be some
correlation between symptoms and plasma lidocaine
concentrations, this is not fully reliable. Diagrammatic
representation of the relationship between symptoms and
plasma lidocaine concentration, as seen in textbooks [97]
(Fig. 2) act as a general guide only. From a safety perspective,
peak plasma concentrations and clinical evidence of toxicity
are related not only to the total dose given (which in itself
needs to be adjusted for the patient’s weight and co-
morbidities) but also to the speed and duration of infusion.
Again, the risk-benefit decision to use i.v. lidocaine needs to
reflect the typeof surgery and thepatient’s condition.
‘Off-label’use
Drug manufacturers must secure a marketing authorisation
(often termed product licence) from the relevant national
authority or agency [98]. Despite this, a substantial
proportion of all prescriptions in many specialties
(particularly paediatrics and palliative care) are written for
licensed drugs given for unlicensed indications or
administration by a route not stated in the marketing
authorisation, which is termed ‘off-label use’. Anaesthesia is
no exception [99] and there are numerous examples of off-
label use including additives or adjuvants in neuraxial or
perineural anaesthesia [100].
Table 1 Plasma lidocaine concentrations from11 studies where sampleswere taken peri-operatively during lidocaine infusions
at three different rates after a bolus of 1.5 mg.kg-1. Values are number ormean (SD).










Koppert et al. [5] Major abdominal surgery 20 1.5 2–4 1.9 (3.1)
Dewinter et al. [65] Laparoscopic sterilisation 40 1.5 > 2 2.5 (1.1)
Weinberg et al. [69] Open radical prostatectomy 36 1.5 2–4 1.4 (0.5)
Martin et al. [79] Total hip arthroplasty 28 1.5 > 2 2.1 (0.4)
El-Tahan et al. [83] Caesarean section 45 1.5 1 2.1 (0.4)
Grigoras et al. [84] Breast surgery 17 1.5 2 1.1 (0.4)
Kaba et al. [31] Laparoscopic colectomy 15 2 2.8 2.4 (0.6)
Striebel et al. [81] Tonsillectomy 20 2 3 2.0 (0.6)
Birch et al. [82] Abdominal hysterectomy 9 2 2 2.1 (0.3)
Lee et al. [85] Off-pumpcardiac surgery 15 2 4.65 2.0 (1.2)
Bryson et al. [38] Abdominal hysterectomy 40 3 1 2.6 (0.6)
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While it is usual to prescribe licensed medicines in
accordance with the terms of their licence, prescribing
outside the license of a medicine is legally permitted.
However, the responsibility for the consequences of
prescribing lies with the prescriber when medicines are
used off-label. When prescribing a medicine off-label, the
prescriber must be satisfied there is sufficient safety and
efficacy evidence, understand the effects and adverse
effects of the medicine, and take responsibility for
prescribing and overseeing the patient’s care, monitoring
and follow-up [101].
Prescribers should provide sufficient information to
patients about the expected benefits and potential risks in
order for them to make an informed decision. It is not
possible to rely on the information provided by the
manufacturer as this only relates to licensed indications.
Given recent legal cases in the UK, there is a requirement “to
take reasonable care to ensure that a patient is aware of any
material risks involved in any recommended treatment, and
of any reasonable alternative or variant treatments” [102].
By prescribing ‘off-label’ prescribers have a duty to take
reasonable care and act in a way consistent with the practice
of a responsible body of their peers of similar professional
standing. In the UK, the Department of Health has issued
provided guidance for the prescribers of unlicensed
medicines [103] and some hospitals and other
organisations have specific policies and patient information.
In the context of i.v. lidocaine infusions, the prescriber
needs to assess each patient individually in order to satisfy
themselves that the drug is necessary for medical reasons,
and theremust be discussion about the benefit and risk with
the patient so that they are able to provide informed
consent.
Detailed recommendations for practice
1 The use of i.v. lidocaine for acute pain should be
ratified and approved by the local hospital and
medication governance committee or equivalent.
Its use should be supported by a local standard
operating procedure, which should include: dosing
advice; required monitoring; recognition of adverse
effects; and treatment of toxicity. An example of a
standard operating procedure is available in the online
Supporting Information (Appendix S2).
2 Before i.v. lidocaine is started there should be a
proper assessment of pain using appropriate
methods. If a patient already has pain, this should be
by standard methods [104]. When the option of i.v.
lidocaine is discussed with the patient pre-operatively,
an appraisal of the patient’s risk of experiencing severe
pain should be made. This may take into account the
extent of the surgical procedure and patient-specific
factors such as pre-existing chronic pain or opioid use.
Intravenous lidocaine should be started only by, or on
the advice of, a consultant anaesthetist/intensivist
experienced in the use of i.v. lidocaine infusions both
within and outside the operating theatre. There must
be confidence that the team running the infusion are
competent to do so and are aware of the local
guideline.
3 Clinicians should carefully consider the relative
contraindications to the use of i.v. lidocaine. These
include: cardiac disease; patients with electrolyte
disorders; patients with seizure disorders, renal or
hepatic impairment, pregnancy/breastfeeding; and
neurological disorders.
4 Where possible, explicit consent should be
obtained frompatients if i.v. lidocaine is to be used.
Given the limited clinical benefit in most patients, the
risks and possible advantages should be clearly
explained to patients. This should follow standard
guidance for the use of medicine for unlicensed
indications [9]. Departments of anaesthesia may wish
to provide written patient information materials to
support the process of informed consent, if time
permits. Patients should be informed about what to





















Figure 1 Meanplasma lidocaine concentrations achieved
by three lidocaine infusion rates. Studies using 1.5mg.kg-1.
h-1: •Koppert et al. [5];▲Dewinter et al. [65]; ⃝Weinberg
et al. [69];■Martin et al. [79];▼El-Tahanet al. [83]; and♦
Grigoras et al. [84]. Studies using 2mg.kg-1.h-1:□Kabaet al.
[31];M Striebel et al. [81];◇Birch et al. [82]; and▽ Lee et al.
[85]. Study using 3mg.kg-1.h-1:●Brysonet al. [38].
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expect and report (if appropriate); this should include
not only symptoms of local anaesthetic toxicity [7], but
also commonly experienced feelings such as euphoria
and facial flushing. Anaesthetists should consider
obtaining provisional consent if there is the possibility
that i.v. lidocainemight be used.
5 Ideal body weight should be used for dose
calculation. This can be calculated using the simple
formula: ideal body weight = (height in cm - 100) for
men; and (height in cm - 105) for women. Ideal and
actual bodyweight are similar if the BMI is < 30 kg.m-2.
6 Intravenous lidocaine should not be used in
patients weighing < 40 kg. For any patient, no
more than120 mg.h-1 should be infused.
7 Intravenous lidocaine should not be used at the
same time as, or within the period of action of other
local anaesthetic interventions. The following
recommendations are based on a consensus among
theworking group:
• Intravenous lidocaine should not be started within
4 h of any nerve or fascial plane block, or infiltration
of laparoscopic port sites.
• No nerve or fascial plane blocks should be
performed until 4 h after completion of an i.v.
lidocaine infusion.
• Boluses of local anaesthetic must not be given into
wound catheters or epidural catheters until 4 h after
completion of an i.v. lidocaine infusion.
• Infusions (without boluses) through wound or
epidural catheters may be started 30 min after an
infusion of i.v. lidocaine has been stopped.
• Topical 5% lidocaine medicated plasters should be
removedbefore starting an i.v. lidocaine infusion.
Figure 2 Typical diagram relating plasma lidocaine concentration to toxic effects. Reproduced, with permission, from Lin et al.
[97].
8 © 2020 TheAuthors.Anaesthesiapublished by JohnWiley & Sons Ltd on behalf of Association of Anaesthetists.
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• Single-shot spinal blockade does not pose a
problem given the small dose of local anaesthetic
used; intrathecal opioids can be used in conjunction
with i.v. lidocaine.
• Concurrent administration of ketamine is acceptable
and has often been tried in patients whose pain is
difficult tomanage, before lidocaine is considered.
8 A loading dose of i.v. lidocaine of no more than
1.5 mg.kg-1, given as an infusion over 10 min is
recommended. Too rapid an infusion is more likely to
cause toxicity [74]. The initial dose should be givenwith
an anaesthetist present; usually the infusion will be
started in the operating theatre, often soon after
induction, where the patient will be closely monitored.
We recommend continuous ECG and pulse oximetry
and regular non-invasive blood pressure (every
5 minutes during initial infusion and for the first
15 minutes thereafter). The initial infusion should be
completed before skin incision, if possible.
9 After an initial loading dose, an infusion of i.v.
lidocaine at 1.5 mg.kg-1.h-1 is recommended,
subject to review and re-assessment. There is no
evidence supporting one dose over another for the
initial dose or subsequent infusion but these doses
have the practical advantage of being numerically the
same. Such a dose usually results in plasma
concentrations < 5 µg.ml-1 [9]. Altering the infusion
rate, for instance in the recovery room or thereafter,
should be a decision taken by a consultant anaesthetist
or intensivist. Frequent changes of infusion rate are to
be discouraged.
10 A suitable infusion device should be used. Pumps
should be dedicated, labelled, lockable and
tamperproof, and adjustable so that both a fixed rate
and fixed upper rate limit can be set. Anti-siphon and
anti-reflux mechanisms should be in place.
Commercially prepared syringes and/or bags of
lidocaine are available and may reduce the risk of
errors in concentration. In any case, a standard
concentration and/or formulation should be used
throughout the hospital, and specified in the standard
operating procedure.
11 The lidocaine infusion should be delivered through
a separate, dedicated cannula. There should be a
minimum flow of sodium chloride 0.9% at 10 ml.h-1,
from a dedicated separate fluid bag, to flush in the
lidocaine and help reduce tracking (redness) up the
vein. This line must have a one-way valve so that
lidocaine cannot track retrogradely into simultaneous
infusions. The infusion line should be labelled with an
ISO-standard grey ‘lidocaine’ label. There should be a
separate lidocainemonitoring chart.
12 The duration of infusion of i.v. lidocaine should not
generally exceed 24 h. In practice, 24 h is often
sufficient as postoperative pain will decrease with time
and other analgesics can still be given. Most patients
do not benefit from prolonged infusion, though some
(for instance, those with chronic pain) might. If the
infusion is to be extended after 24 h, this decision
should be made by a consultant anaesthetist or
intensivist and/or the acute pain team and be within
the scope of the relevant hospital guidelines. The
infusion rate should also be reduced to 50%.
13 Outside the operating theatre/recovery room,
patients receiving i.v. lidocaine infusions should
ideally be managed in a monitored bedspace such
as a high dependency unit (level 2 care).
Observations should be made every 15 min for the
first hour, then hourly as a minimum thereafter
(increased as necessary). Nurses should be trained in
the signs of toxicity; an example of educational
material for this purpose is available in the online
Supporting Information (Appendix S3). ECG
monitoring should be continued in the high
dependency area, although it should be noted that
cardiovascular signs and ECG changes are late
manifestations of lidocaine toxicity. Neurological
symptoms and signs are the earliest and include peri-
oral tingling, tinnitus, light-headedness and
restlessness. Particular vigilance is needed in patients
with existing comorbidity. The hospital acute pain
team should be involved inmonitoring and follow-up.
14 Lipid emulsion 20% should be readily available
wherever i.v. lidocaine is used, and staff should
knowwhere it is kept. This treatment [105] should be
used according to the Association of Anaesthetists’
management guideline [106].
15 Clinicians should remember the possibility of
toxicity even though there may be other
explanations for a given clinical presentation. In the
event of an adverse incident in a patient receiving an
i.v. lidocaine infusion: preserve the pump with its
settings and memory intact in order to enable
investigation; and take blood for later analysis of
lidocaine levels in both ethylenediaminetetra-acetic
acid (EDTA) tubes and lithium heparin tubes, as the
local requirements for assays vary.
In summary, i.v. lidocaine appears to offer some
benefits to people undergoing surgery but these must be
© 2020 The Authors.Anaesthesiapublished by JohnWiley & Sons Ltd on behalf of Association of Anaesthetists. 9
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balanced against the possible risks. The nature and
likelihood of specific risks and benefits is likely to vary across
different types of patient and different surgical operations.
Careful use of i.v. lidocaine canminimise the risks.
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